Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.

× No keyword cloud information.

15 in total

1. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.

Authors: Yudong Su; Xiang Long; Yang Song; Peng Chen; Shanqing Li; Huaxia Yang; Pancheng Wu; Yanyu Wang; Zhongxing Bing; Zhili Cao; Lei Cao; Yijun Wu; Zhe Zhang; Jing Liu; Bing Li; Jianxing Xiang; Ke Ma; Tengfei Zhang; Lu Zhang; Xinru Mao; Hao Liu; Puyuan Xing; Naixin Liang
Journal: Target Oncol Date: 2019-04 Impact factor: 4.493

2. Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.

Authors: Ying-Hsia Chu; Jada Barbee; Soo-Ryum Yang; Jason C Chang; Priscilla Liang; Kerry Mullaney; Roger Chan; Paulo Salazar; Ryma Benayed; Michael Offin; Alexander Drilon; Marc Ladanyi; Khedoudja Nafa; Maria E Arcila
Journal: J Mol Diagn Date: 2022-04-14 Impact factor: 5.341

3. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.

Authors: Wenbin Li; Zhihui Zhang; Lei Guo; Tian Qiu; Yun Ling; Jian Cao; Huiqin Guo; Huan Zhao; Lin Li; Jianming Ying
Journal: Oncotarget Date: 2016-02-16

4. Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients.

Authors: Lin Yang; Yun Ling; Lei Guo; Di Ma; Xuemin Xue; Bingning Wang; Junling Li; Jianming Ying
Journal: Chin J Cancer Res Date: 2016-10 Impact factor: 5.087

Review 5. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Alessandro D'Aveni; Grazia Marabello; Alessia Liguori; Elisa Giovannetti; Niki Karachaliou; Maria Gonzalez Cao; Rafael Rosell; Giuseppe Altavilla
Journal: Drug Des Devel Ther Date: 2017-07-05 Impact factor: 4.162

6. Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation.

Authors: Viola W Zhu; Alexa B Schrock; Thangavijayan Bosemani; Bryan S Benn; Siraj M Ali; Sai-Hong Ignatius Ou
Journal: Lung Cancer (Auckl) Date: 2018-11-08

7. Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.

Authors: Wei Ma; Lei Guo; Ling Shan; Xiuyun Liu; Ning Lyu; Jianming Ying
Journal: Sci Rep Date: 2017-09-08 Impact factor: 4.379

Review 8. ALK-rearrangement in non-small-cell lung cancer (NSCLC).

Authors: Xue Du; Yun Shao; Hai-Feng Qin; Yan-Hong Tai; Hong-Jun Gao
Journal: Thorac Cancer Date: 2018-02-28 Impact factor: 3.500

9. Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin

Authors: Samar Moatter; Namrah Anwar; Tariq Moatter; Shahid Pervez
Journal: Asian Pac J Cancer Prev Date: 2018-06-25

10. ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Authors: Florian Cabillic; Paul Hofman; Marius Ilie; Nir Peled; Maximilian Hochmair; Manfred Dietel; Maximilian Von Laffert; John R Gosney; Fernando Lopez-Rios; Gilles Erb; Uwe Schalles; Fabrice Barlesi
Journal: ESMO Open Date: 2018-09-17